Viking Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VKTX research report →
About the company
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß).
- CEO
- Brian Lian
- IPO
- 2015
- Employees
- 45
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $4.35B
- P/E
- -9.04
- P/S
- 0.00
- P/B
- 8.62
- EV/EBITDA
- -8.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.31%
- ROIC
- -100.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-359,639,000 · -227.05%
- EPS
- $-3.19 · -215.84%
- Op Income
- $-393,342,000
- FCF YoY
- -217.45%
- 52W High
- $43.15
- 52W Low
- $22.96
- 50D MA
- $31.87
- 200D MA
- $32.92
- Beta
- 0.68
- Avg Volume
- 2.37M
Get TickerSpark's AI analysis on VKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Chen Hubert C | other | 190,000 |
| Jun 1, 26 | Chen Hubert C | other | 0 |
| Mar 10, 26 | Aubuchon Neil William | buy | 4,475 |
| Jan 12, 26 | Aubuchon Neil William | other | 180,000 |
| Jan 12, 26 | Aubuchon Neil William | other | 0 |
| Jan 2, 26 | ZANTE GREG | other | 32,049 |
| Jan 5, 26 | ZANTE GREG | sell | 31,961 |
| Jan 2, 26 | ZANTE GREG | other | 41,000 |
| Jan 5, 26 | ZANTE GREG | sell | 13,900 |
| Jan 5, 26 | ZANTE GREG | sell | 10,300 |
Our VKTX coverage
Recent articles, reports, and earnings notes.
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Should You Buy the Palatin Technologies IPO? Here's the Setup
Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.
Want a deeper read on VKTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.